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ABSTRACT   
In this study, the percentages of study variables including age, gender, residence, family history between 
study groups including patients with psoriasis disease and control group, the results showed presence of 
There were substantial differences in age between study groups (P0.05), but no huge differences in sexual 
identity (P>0.05), housing (P>0.05), or family background (P>0.05). Meanwhile the terms of BMI, there's 
no big variation between categories (p> 0.05). They were chosen in this way to obtain the patients with 
psoriasis disease (27.70±0.80) and control group (27.80±0.50). Per the PASI, 8% of sick people had mild 
psoriasis (PASI3), while 55% had modest psoriasis (PASI 3-10) whereas, 37% had severe type (PASI >10). 
In addition, the mean differences of HbA1C, plasma glucose and plasma protein according to study groups 
including (patients with psoriasis disease and control group) was no significant differences between means 
of HbA1C, plasma glucose and plasma protein according to study group (P 0>0.05). 
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Psoriasis is an allergic disease (a disease with idiopathic inflammation induced by immune system distribution) 
that creates chronic state [1]. Slightly elevated plaques (plaques may look various depending on skin types) and 
dimensions on the skin may be marked signs of inflammation [2]. This happens because a hyperactive immune 
response accelerates skin cell proliferation [3]. In a month cavity, normal skin cells hyperplasia and shed (fall 
off) accrue [4]. It was happening for three or four days [5]. Rather than shedding, dermal cell accumulate on the 
outer layer of epithelium of the skin [6]. Some patients claim that their plaques itch, burn, and hurt [7]. Plaques 
signs and scales can arise everywhere on the skin, but they are most prevalent on the wrists, ankles, and scalp 
[8]. Psoriasis lead to severe inflammatory response can have an effect on certain body parts and tissues within 
the body [9]. Patients with psoriasis may also have other health condensation [10]. One third of psoriasis patients 
will develop inflammation of joints (PsA) [11]. PsA symptoms include swelling, stiffness, and pain in the joints, 
unfortunately PsA frequently misdiagnosed in mildly cases and should be treat rapidly to avoid permanent joint 
damage [12]. Symptoms can appear at any age especially the ages from 15 to 25 and all type of skin and gender 
[13]. Pustular kind is characterized by red, cracked skin with small pustules on the armpits and lower leg [14]. 
Other Type of psoriasis was Guttate, which little, red patches appear on the chest and legs, and it usually occur 
in children. Also respiratory problems accrued like strep infection in throat, and tonsillitis, stress, skin injury 
[15]. The third type was Inverse, It causes brilliant red, gleaming sores in skin creases like the armpits [16]. The 
last type of psoriasis was Erythrodermic type is characterized by a fiery hyperemic skin and the shedding of 
scales caused severe Diseases, sunburn blisters, certain medicines, and stopping specific forms of psoriasis 
therapy are also factors to consider directly to avoid the serious illness [17]. 
 
2. Materials and Methods 
The present study is an observational case control design. The data of study were collected in the period from 
 PEN Vol. 9, No. 3, July 2021, pp.393-399 
394 
March 2021 to June 2021. The study was conducted in clinical private in AL-Anbar Government, Iraq. A total 
number of subjects involved in this study was 200 patients (100 patients suffering from psonasis disease and 
100 as control healthy), from both sex (male and female), with age range 15-65 years. All patients and control 
were from the same ethnic group (Arabic).A valid consent was achieved from each patients before their 
inclusion in the study. Questionnaire taken from the patients and case sheet included age, gender, residence, 
smoking locally treatment, treatment by systemic drug and family history. The psoriasis patients who diagnoses 
as patients with eczema.  Any patients were given both local and systemic treatment.drug treatment, patients 
were suffering from diabetic, and obesity patients.  Five ml of blood were obtained from each subject by vein 
puncture, it was put into EDTA tubes with sodium citrate for obtained plasma, stored in (-20˚C) in order to be 
used in HbA1C, plasma glucose, and plasma protein. 
 
2.1. BMI measurement 
Regard to World Health Organization criteria, all patients are classified according BMI (WHO, 2004). 
Depending on the flowing, BMI (kg/m2) = weight (kg) / height (m2). 
Underweight ≥ 18.5 
Normal (18.5 - 24.9). 
Overweight (25-29.9). 
Obese ≤ 30. 
 
2.2. Distribution of psoriasis as a measurement of how severe it is 
 
According to PASI, mild cases (PASI <3), moderate diseases (PASI 3-10) and severe onset (PASI >10) (Mattei 
et al., 2014). 
 
2.3. Estimation of HbA1C 
This biomarker was determination according to study of Hamaguchi et al., as reported in [18]. 
 
2.4. Determination of plasma glucose 
This biomarker was determination according to study of Frank et al., (2012). 
 
2.4. Determination of plasma protein 
It was prepared by 25 ml serum to chib, and calculated by dry- chemistry (Dri-chem Fujifilm) (Japan). 
2.5. Statistical analysis 
SPSS version 23 was used for statistical analysis. (Means ± SD) was used to depict continuous variables. To 
compare the means of two groups, a student t-test was utilized. 
3. Results and discussion 
In this study, the percentages of study variables including age, gender, residence, family history between study 
groups including patients with psoriasis disease and control group were shown in Table 1. The findings revealed 
that there were significant variations in age (P0.05) between research groups, but no significant variations in 
gender (P>0.05), residency (P>0.05), or familiar (P >0.05). 
 
Table 1. Distribution of study groups by socio-demographic characteristics 
Study variables 
Study groups (%) 















P ≥ 0.05* 
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Study variables 
Study groups (%) 
P-value patients with 
psoriasis disease 
Healthy control 










P > 0.05 










P > 0.05 









24(24.0%) P > 0.05 
Total 100(100.0%) 100 (100.0%) 
* p value ≤ 0.05 was significant.   
 
There was no discernible important results appear to compare between the two groups. Subjects groups are in 
the BMI (p>0.05). They were chosen in this way to obtain the patients with psoriasis disease (27.70 ±0.80) along 
with  control group (27.80 ±0.50) as shown Table 2. 
 
Table 2.  General characterization of patients with psoriasis disease and control group according to BMI as 
mean  ±SD 
Parameter Patients with psoriasis disease Control group p-value 
Mean±SD Mean±SD 
BMI (Kg/M2 ) 27.70±0.80 27.80±0.50 P > 0.05 
 
 
* p value ≤ 0.05 was significant.   
 
As per the PASI, 8% of patients had mild psoriasis (PASI3), 55% had moderate psoriasis (PASI3-10), and 37% 
had severe psoriasis (PASI>10), as indicated in Table 3. 
 
Table 3. Distribution of cases according to PASI 
PASI No.  of patients % 
mild 8 8% 
Moderate 55 55% 
Severe 37 37% 
 
The mean differences of HbA1C, plasma glucose and plasma protein according to study groups including 
(patients with psoriasis disease and control group) was investigated in Table 4. There were no significant 
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changes in HbA1C means, according to the findings of  plasma glucose and plasma protein according to study 
group (P 0>0.05). 
 
Table 4.  Mean differences of HbA1C, plasma glucose and plasma protein according to study groups 
including (patients with psoriasis disease and control group). 
 
Biomarker Patients with psoriasis disease Con. Group  p- 
value 
Mean ± SD Mean ± SD 
HbA1C (%) 7.85±0.86 7.22±1.09 P > 
0.05 
plasma glucose (mg/dl) 9.32±3.36 12.63±6.32 P > 
0.05 
plasma protein (g\L) 28.80±4.08 34.21±8.78 P > 
0.05 
 
* p value ≤ 0.05 was significant.   
 
4. Discussion 
Psoriasis is increasingly being viewed as a systemic illness, with experts believing that dermatological 
symptoms are simply one aspect of the disease. Its link to the metabolic syndrome is particularly significant 
[19]. Psoriasis is believed to afflict 2–4% of the industrialized global population [20]. Psoriasis rates vary by 
age, geography, and ethnicity; these variances are considered to be caused by a mix of ecological and hereditary 
factors [21]. It may strike anyone at any age, although it most frequently strikes people between the ages of 15 
and 25.Psoriasis is diagnosed in around a third of adults before they reach the age of 20 [22]. According to 
several research, the typical age of start for psoriasis was 33 years old, with 75 percent of cases occurring even 
before age reached 46 [23]. Others believed that psoriasis onset was bimodal, with two peaks of the illness-the 
first at 16 to 22  and the second at 57 to 60 [24]. However, there are few research on the epidemiology or 
prevalence of psoriasis in kids, and those that do appear show that psoriasis in children varies greatly across 
Taiwan, China, and the United States [25] and 1.37% during life hits in 0–17-year-old children in Germany 
[26]. The major seeking study on prevalence among children was done out in Germany [27]. Psoriasis was 
found to be 0.40 percent common in children under 18., according to statistics from a health insurance company 
database of around 1.3 million people, and grew fairly linearly over time [28]. A research record by Sabry et 
al., [29] reported  that, the occurrence of disease in people with age 18 years and less was 0.05%. The paper of 
Vos et al. [30], explained the 50–69 year old age group had the highest disease burden, and psoriasis produced 
a somewhat greater burden in adult males than adult females up to 75 years old so both gender are affected [31]. 
Psoriasis affects both men and women in equal amounts [32]. Furthermore, other research found that psoriasis 
is also more prevalent in males, according to all investigations that provided distribution by sex [33-34].The 
figures given are not statically important [35-36]. This is a topic that needs to be looked into more, particularly 
the distinction between hereditary and behavioral variables [37]. The severity of the disease has been linked to 
a higher incidence of certain risk factors in the past [38]. In the lack of reliable data, research have focused on 
the therapy spectrum as a measure for intensity [39]. Lesion area and severity index are then used as a severity 
index (PASI) was employed, which is extensively used to evaluate severity in both research and clinical settings 
[40].Few research have been published to date that investigate the link between the distribution of psoriasis risk 
factors and PASI, and the relationship has not been convincingly shown in Asian psoriasis patients [41, 42].  
 
5. Conclusion  
 
Patients with psoriasis disease is related to the only patient's age, but it has nothing to do with demographic data 
as gender, residence, family history and BMI. Furthermore, the allocation of patients as per the eczema area 
rating scale was examined, moderate psoriasis was a predominant in Al-Anbar government, also, this disease 
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was not related to some biomarkers determination like HbA1C, plasma glucose and plasma protein.  
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